US 12,391,677 B2
Thyroid hormone receptor agonists
Xing Dai, Shanghai (CN); Yaolin Wang, Shanghai (CN); Yueheng Jiang, Shanghai (CN); Yanqin Liu, Shanghai (CN); Zixing Han, Shanghai (CN); Zhenwu Wang, Shanghai (CN); Liangshan Tao, Shanghai (CN); and Zhe Shi, Shanghai (CN)
Assigned to INVENTISBIO CO., LTD., Shanghai (CN)
Appl. No. 17/284,149
Filed by INVENTISBIO CO., LTD., Shanghai (CN)
PCT Filed Oct. 11, 2019, PCT No. PCT/CN2019/110494
§ 371(c)(1), (2) Date Apr. 9, 2021,
PCT Pub. No. WO2020/073974, PCT Pub. Date Apr. 16, 2020.
Claims priority of application No. PCT/CN2018/109942 (WO), filed on Oct. 12, 2018; and application No. PCT/CN2019/075501 (WO), filed on Feb. 20, 2019.
Prior Publication US 2021/0355110 A1, Nov. 18, 2021
Int. Cl. C07D 403/12 (2006.01); A61K 31/501 (2006.01); A61K 31/53 (2006.01); A61P 5/16 (2006.01); C07D 401/14 (2006.01); C07D 403/10 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07F 9/6509 (2006.01)
CPC C07D 403/12 (2013.01) [A61K 31/501 (2013.01); A61K 31/53 (2013.01); A61P 5/16 (2018.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07D 403/14 (2013.01); C07D 405/14 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07F 9/650905 (2013.01)] 10 Claims
 
1. A compound selected from Compound Nos. 27, 35, and 66, or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry